Geode Capital Management LLC Purchases 608,950 Shares of Hims & Hers Health, Inc. $HIMS

Geode Capital Management LLC grew its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 12.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,509,764 shares of the company’s stock after buying an additional 608,950 shares during the period. Geode Capital Management LLC’s holdings in Hims & Hers Health were worth $183,485,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Farallon Capital Management LLC boosted its stake in Hims & Hers Health by 30.8% in the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock worth $609,561,000 after purchasing an additional 2,533,271 shares in the last quarter. Invesco Ltd. grew its position in Hims & Hers Health by 62.7% during the 3rd quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock worth $235,525,000 after purchasing an additional 1,600,004 shares during the last quarter. Clear Street Group Inc. purchased a new stake in Hims & Hers Health during the 3rd quarter worth approximately $87,372,000. Vanguard Group Inc. grew its position in Hims & Hers Health by 7.2% during the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock worth $679,456,000 after purchasing an additional 1,407,651 shares during the last quarter. Finally, BIT Capital GmbH grew its position in Hims & Hers Health by 73.8% during the 3rd quarter. BIT Capital GmbH now owns 2,210,384 shares of the company’s stock worth $125,373,000 after purchasing an additional 938,728 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Price Performance

NYSE:HIMS opened at $27.49 on Thursday. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56. The firm has a market cap of $6.36 billion, a price-to-earnings ratio of -305.46, a price-to-earnings-growth ratio of 53.38 and a beta of 2.37. The company has a 50 day moving average price of $24.37 and a 200-day moving average price of $27.15. Hims & Hers Health, Inc. has a 1-year low of $13.74 and a 1-year high of $70.43.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.44). The firm had revenue of $608.10 million for the quarter, compared to analysts’ expectations of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. Hims & Hers Health’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period last year, the firm earned $0.20 earnings per share. Equities research analysts forecast that Hims & Hers Health, Inc. will post 0.04 EPS for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on HIMS. Weiss Ratings downgraded shares of Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research report on Tuesday, May 12th. Morgan Stanley dropped their target price on shares of Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 24th. Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $25.00 target price on shares of Hims & Hers Health in a research report on Tuesday, May 5th. Finally, Bank of America dropped their target price on shares of Hims & Hers Health from $28.00 to $25.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 26th. Four equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $28.70.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers completed its acquisition of Eucalyptus, expanding into Australia, Canada, Germany, and Japan and strengthening its global telehealth and weight-management footprint. Hims & Hers Completes Acquisition of Eucalyptus, Advancing its Position as the World’s Largest Consumer Health Platform
• Positive Sentiment: The Eucalyptus deal supports Hims & Hers’ long-term growth story by adding established brands and clinical infrastructure in key international markets. HIMS Stock Slips Despite Early Eucalyptus Buyout Close: Analyst Sees 10% Downside On GLP-1 Profit Risks
• Neutral Sentiment: Investors are re-evaluating Hims & Hers’ valuation after sharp recent swings, with the stock showing strong short-term gains but weaker year-to-date performance. Taking A Fresh Look At Hims & Hers Health (HIMS) Valuation After Recent Share Price Swings
• Negative Sentiment: U.S. Senator Jim Banks is pressing the FDA to review Hims & Hers’ GLP-1 advertising, pricing, and subscription practices, adding new political and regulatory risk around a key growth area. Political Scrutiny Tests Hims And Hers GLP1 Weight Loss Growth Story
• Negative Sentiment: One analyst warned that GLP-1 profitability could face pressure, which may weigh on investor confidence despite the company’s growth initiatives. HIMS Stock Slips Despite Early Eucalyptus Buyout Close: Analyst Sees 10% Downside On GLP-1 Profit Risks

Insider Activity

In other news, insider Soleil Boughton sold 9,463 shares of Hims & Hers Health stock in a transaction that occurred on Monday, April 20th. The shares were sold at an average price of $30.00, for a total transaction of $283,890.00. Following the completion of the transaction, the insider directly owned 299,368 shares of the company’s stock, valued at $8,981,040. The trade was a 3.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David B. Wells bought 48,400 shares of the business’s stock in a transaction dated Tuesday, May 26th. The shares were purchased at an average cost of $24.23 per share, with a total value of $1,172,732.00. Following the completion of the acquisition, the director owned 224,417 shares in the company, valued at approximately $5,437,623.91. This represents a 27.50% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders sold 212,807 shares of company stock worth $5,473,644. 11.76% of the stock is currently owned by corporate insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.